Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 9/2017

01-11-2017 | Original Article

Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer

Authors: Yasemin Sanli, Serkan Kuyumcu, Oner Sanli, Fikret Buyukkaya, Ayça İribaş, Goksel Alcin, Emin Darendeliler, Yasemin Ozluk, Sevda Ozel Yildiz, Cüneyt Turkmen

Published in: Annals of Nuclear Medicine | Issue 9/2017

Login to get access

Abstract

Aim

To investigate the relationship between serum PSA level, Gleason score of PCa and the outcomes of Ga68-PSMA PET/CT in patients with recurrent PCa.

Methods

A total of 109 consecutive patients (median age 71 years; range 48–89 years) who had PSA recurrence after RP and/or hormonotherapy and/or radiotherapy were included in this study. Local recurrences, lymph node metastasis (pelvic, abdominal and/or supradiaphragmatic), bone metastases (oligometastatic/multimetastatic) and other metastatic sites (lung, liver, brain, etc) were documented.

Results

In 91(83.4%) patients at least one lesion characteristic for PCa was detected by68Ga-PSMA PET/CT. The median serum total PSA (tPSA) was 6.5 (0.2–640) ng/ml.There was a significant difference between 68Ga-PSMA PET/CT positive and negative patients in terms of serum total PSA value. No statistical significance was found between positive and negative 68Ga-PSMA PET/CT findings in terms of Gleason score. Local recurrence was detected in 56 patients. whereas lymph node metastases were demonstrated in 46 patients. Pelvic nodal disease was the most frequent presentation followed by abdominal and supradiaphragmaticnodal involvement. Bone metastases [oligometastasis, (n = 20); multimetastasis, (n = 35)⦌ were also detected in 55 patients. In the ROC analysis for the study cohort, the optimal cut-off value of total serum PSA was determined as 0.67 ng/ml for distinguishing between positive and negative 68Ga-PSMA PET/CT images, with an area under curve of 0.952 (95% CI 0.911–0.993).

Conclusions

68Ga-PSMA PET/CT was found to be an effective tool for the detection of recurrent PCa. Even though no relationship was detected between the GS and 68Ga-PSMA PET/CT findings, serum total PSA values may be used for estimating the likelihood of positive 68Ga-PSMA PET/CT results.
Literature
1.
Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736–41.CrossRefPubMed
2.
Khuntia D, Reddy CA, Mahadevan A, Klein EA, Kupelian PA. Recurrence free survival rates after external beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate specific antigen era: what should we expect? Cancer. 2004;100:1283–92.CrossRefPubMed
3.
Denis LJ, Keuppens H, Smith PH, et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC data center. EurUrol. 1998;33:155–151.
4.
Yao HI, KH Hong M, Corcoran NM, Siva S, Foroudi F. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol. 2014;10(4):308–21.CrossRefPubMed
5.
6.
O’Keefe DS, Su SL, Bacich DJ, et al. Mapping, genomic organization and promoter analysis of the human prostatespecific membrane antigen gene. Biochim Biophys Acta. 1998;1443:113–27.CrossRefPubMed
7.
Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209.CrossRefPubMed
8.
Stevens DJ, Sooriakumaran P. Oligometastatic prostate cancer. Curr Treat Opt Oncol. 2016;17:62.CrossRef
9.
Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(2):253–63.CrossRefPubMed
10.
Igerc I, Kohlfürst S, Gallowitsch HJ, et al.The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(5):976–83.CrossRefPubMed
11.
Ceci F, Uprimny C, Nilica B, et al. (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging. 2015;42(8):1284–94.CrossRefPubMed
12.
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.CrossRefPubMed
13.
Giesel FL, Fiedler H, Stefanova M, et al. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(12):1794–800.CrossRefPubMedPubMedCentral
14.
Heidenreich A, Bellmunt J, Bolla M, et al. European Association of Urology.EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localiseddisease. Eur Urol. 2011;59(1):61–71.CrossRefPubMed
15.
Flanigan RC, McKay TC, Olson M, Shankey TV, Pyle J, Waters WB. Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy. Urology. 1996;48(3):428–32.CrossRefPubMed
16.
Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. ClinRadiol. 2008;63(4):387–95.
17.
Engeler CE, Wasserman NF, Zhang G. Preoperative assessment of prostatic carcinoma by computerized tomography.Weaknesses and new perspectives. Urology. 1992;40(4):346–50.CrossRefPubMed
18.
Budaus L, Leyh-Bannurah SM, Salomon G, et al. Initial experience of 68Ga-PSMA PET/CT imaging in high risk prostate cancer patients prior to radical prostatectomy. EurUrol. 2016;69:393–6.
19.
Bubendorf L, Schopher A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1.589 patients. Hum Pathol. 2000;31(5):578–83.CrossRefPubMed
20.
Pyka T, Weirich G, Einspieler I, Maurer T, Theisen J, Hatzichristodoulou G, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive of lung lesions in patients with prostate cancer. J Nucl Med. 2016;57:367–71.CrossRefPubMed
21.
Chakraborty PS, Kumar R, Tripathi M, Das CJ, Bal C. Detection of brain metastasis with 68 Ga-labeled PSMA ligand PET/CT: a novel radiotracer for imaging of prostate carcinoma. ClinNucl Med. 2015 Apr;40(4):328–9.
22.
Afshar-Oromieh A, Giesel FL, Linhart HG, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39(9):1409–15.CrossRefPubMed
23.
Kanthan GL, Drummond J, Schembri GP, Izard MA, Hsiao E. Follicular. Thyroid adenoma showing avid uptake on 68 Ga PSMA-HBED-CC PET/CT. ClinNucl Med. 2016;41(4):331–2.
24.
Perner S, Hoter MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696–701.CrossRefPubMed
Metadata
Title
Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer
Authors
Yasemin Sanli
Serkan Kuyumcu
Oner Sanli
Fikret Buyukkaya
Ayça İribaş
Goksel Alcin
Emin Darendeliler
Yasemin Ozluk
Sevda Ozel Yildiz
Cüneyt Turkmen
Publication date
01-11-2017
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 9/2017
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-017-1207-y

Other articles of this Issue 9/2017

Annals of Nuclear Medicine 9/2017 Go to the issue

Original Article

Comparison of image quality between step-and-shoot and continuous bed motion techniques in whole-body 18F-fluorodeoxyglucose positron emission tomography with the same acquisition duration

Original Article

18F-FDG PET radiomics approaches: comparing and clustering features in cervical cancer

Original Article

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia

Original Article

Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria

Original Article

Effects of chronic kidney disease on myocardial washout rate of thallium-201 in patients with normal myocardial perfusion on single photon emission computed tomography

Original Article

Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts